Palvella Therapeutics Net Profit Margin Growth & History (PVLA)
Palvella Therapeutics's net profit margin was 48.28% for fiscal 2023.
View full Palvella Therapeutics company overviewPalvella Therapeutics annual net profit margin history
| Fiscal year | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| 2023 | 2023-12-31 | 48.28% | +178.94 pp |
| 2022 | 2022-12-31 | −130.66% | +33.04 pp |
| 2021 | 2021-12-31 | −163.70% | −8.00 pp |
| 2020 | 2020-12-31 | −155.70% | −97.35 pp |
| 2019 | 2019-12-31 | −58.35% | +39.83 pp |
| 2018 | 2018-12-31 | −98.19% | −28.37 pp |
| 2017 | 2017-12-31 | −69.82% | +321.18 pp |
| 2016 | 2016-12-31 | −391.00% | +88.50 pp |
| 2015 | 2015-12-31 | −479.50% | −295.91 pp |
| 2014 · Dec 31 | 2014-12-31 | −183.59% | −184.13 pp |
| 2013 | 2013-12-31 | 0.53% | — |
Palvella Therapeutics quarterly net profit margin
| Fiscal quarter | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| Q1 2024 | 2024-03-31 | −42,266.67% | −41610.80 pp |
| Q4 2023 | 2023-12-31 | 3,695.03% | +3836.94 pp |
| Q3 2023 | 2023-09-30 | −69.06% | +121.39 pp |
| Q2 2023 | 2023-06-30 | 19.79% | +317.89 pp |
| Q1 2023 | 2023-03-31 | −655.87% | −610.24 pp |
| Q4 2022 | 2022-12-31 | −141.92% | −18.94 pp |
| Q3 2022 | 2022-09-30 | −190.45% | +403.73 pp |
| Q2 2022 | 2022-06-30 | −298.10% | +312.06 pp |
| Q1 2022 | 2022-03-31 | −45.63% | −17.56 pp |
| Q4 2021 | 2021-12-31 | −122.98% | +825.64 pp |
| Q3 2021 | 2021-09-30 | −594.18% | −40.14 pp |
| Q2 2021 | 2021-06-30 | −610.16% | −564.87 pp |
| Q1 2021 | 2021-03-31 | −28.06% | +12.42 pp |
| Q4 2020 | 2020-12-31 | −948.62% | −943.99 pp |
| Q3 2020 | 2020-09-30 | −554.03% | −536.16 pp |
| Q2 2020 | 2020-06-30 | −45.29% | +193.02 pp |
| Q1 2020 | 2020-03-31 | −40.48% | +96.87 pp |
| Q4 2019 | 2019-12-31 | −4.62% | +243.60 pp |
| Q3 2019 | 2019-09-30 | −17.88% | +60.27 pp |
| Q2 2019 | 2019-06-30 | −238.31% | −236.50 pp |
| Q1 2019 | 2019-03-31 | −137.35% | +115.67 pp |
| Q4 2018 | 2018-12-31 | −248.23% | −289.49 pp |
| Q3 2018 | 2018-09-30 | −78.15% | +101.60 pp |
| Q2 2018 | 2018-06-30 | −1.81% | +542.44 pp |
| Q1 2018 | 2018-03-31 | −253.02% | +342.21 pp |
| Q4 2017 | 2017-12-31 | 41.27% | +281.82 pp |
| Q3 2017 | 2017-09-30 | −179.76% | +609.56 pp |
| Q2 2017 | 2017-06-30 | −544.25% | +4.12 pp |
| Q1 2017 | 2017-03-31 | −595.23% | −261.45 pp |
| Q4 2016 | 2016-12-31 | −240.55% | −104.92 pp |
| Q3 2016 | 2016-09-30 | −789.32% | +156.69 pp |
| Q2 2016 | 2016-06-30 | −548.37% | +1654.52 pp |
| Q1 2016 | 2016-03-31 | −333.78% | +1368.60 pp |
| Q4 2015 | 2015-12-31 | −135.63% | −8.42 pp |
| Q3 2015 | 2015-09-30 | −946.01% | +9853.77 pp |
| Q2 2015 | 2015-06-30 | −2,202.89% | −1790.18 pp |
| Q1 2015 · Mar 31 | 2015-03-31 | −1,702.38% | −1645.57 pp |
| Q4 2014 | 2014-12-31 | −127.21% | — |
| Q1 2015 · Sep 30 | 2014-09-30 | −10,799.78% | — |
| Q4 2014 | 2014-06-30 | −412.71% | — |
| Q1 2014 | 2014-03-31 | −56.81% | — |
Palvella Therapeutics net profit margin trends
Over the last five fiscal years, Palvella Therapeutics's net profit margin increased from −98.19% to 48.28%, a change of +146.47 percentage points. The latest reported quarter, Q1 2024, shows −42,266.67%.
What net profit margin means
Net profit margin measures the percentage of revenue remaining as net income after operating costs, interest, taxes, and other expenses. It shows how much bottom-line profit or loss a company generates from each dollar of revenue.
How net profit margin is calculated
TickerStat calculates net profit margin as SEC-reported net income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Palvella Therapeutics source filings ↗